Posts by tokyoseminole

Upcoming Catalyst review   http://biotechtrader34.blogspot.com/p/phase-2-phase-3-calendar.html   Drug: HEPLISAV™ Hepatitis B vaccine Target: Adult hepatitis B vaccine that is designed to provide rapid and...

Upcoming Catalyst summary   http://biotechtrader34.blogspot.com/p/phase-2-phase-3-calendar.html   Drug: Probuphine™ Target: sublingual formulation for the treatment of opioid addiction. Catalyst: randomised,...

Catalyst coming up -     http://biotechtrader34.blogspot.com/p/phase-2-phase-3-calendar.html   Drug:  Ixmyelocel-T Target: Patient-specific multicellular therapy expanded from a patient's...

Busy week -   LCI - Approved PTIE/DRRX - CRL given FSCS - Approved   not much in July.. but a few ph3 update catalysts like $DVAX ..   also $ALXA NDA re-submission in July

and now LCI  down 4%

Lannett Receives FDA Approval for Morphine Sulfate Oral Solution NDA Last update: 6/24/2011 9:34:00 AM PHILADELPHIA, Jun 24, 2011 (BUSINESS WIRE) -- Lannett Company, Inc. (LCI) today announced that the U.S. Food and Drug...

FCSC LaViv approved,   LCI tomorrow -

LaViv approved.. PR out at 9:15   http://biotechtrader34.blogspot.com/2011/06/fcsc-laviv-approved.html    

  Acura Pharmaceuticals (ACUR): FDA Approves Acurox, Named Oxecta   FDA Spokesperson, Karen Riley, has informed me via email that the “Fda approved Acurox – a couple minutes ago different name...

My Watchlist for week of 6/20   FCSC - PDUFA 6/22 azficel-T, proposed brand name laViv®,” LCI - PDUFA 6/23 Morphine Sulfate Oral Solution. ALXA - new drug application (NDA) on AZ-004 (Staccato loxapine) for the treatment of...